CRISPR/Cas9-The ultimate weapon to battle infectious diseases?
M Doerflinger, W Forsyth, G Ebert, M Pellegrini, MJ Herold
Cellular Microbiology | WILEY | Published : 2017
Awarded by National Health and Medical Research Council Australia
M. J. H. is supported by the National Health and Medical Research Council Australia (Project Grant GNT 1049720) and Cancer Council Victoria Venture Grant. M. P., M. D., G. E., and W. F. 's work is supported by National Health and Medical Research Council Australia (Grants 1006592, 1045549, and 1065626 to M. P.), the Sylvia and Charles Viertel Senior Medical Research Fellowship (M. P.), the CASS Foundation (G. E.), the Australian Centre for HIV and Hepatitis Virology Research (G. E.), the Victorian State Government Operational Infrastructure Support, and the Independent Research Institutes Infrastructure Support Scheme of the Australian Government National Health and Medical Research Council. The Walter and Eliza Hall Institute of Medical Research have a research license agreement with TetraLogic Pharmaceuticals (Malvern, PA, USA), the manufactures of the cIAP antagonist birinapant. Tetralogic has filed a PCT on behalf of the Walter and Eliza Hall Institute of Medical Research. M. P. provided consultative advice to, and was on the scientific advisory board of, TetraLogic Pharmaceuticals.